Argatroban: Update

American Heart Journal

Volumn 151, Issue 6, 2006, Pages 1131-1138

  Yeh, Robert W ^a   Jang, Ik Kyung ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; EPTIFIBATIDE; ERYTHROMYCIN; HEPARIN; HIRULOG; LEPIRUDIN; PHENPROCOUMON; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR; WARFARIN;

ARTERY THROMBOSIS; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; HEART INFARCTION; HEART SURGERY; HEMODIALYSIS; HUMAN; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; THROMBOSIS; VASCULAR PATENCY;

ANIMALS; ANTICOAGULANTS; CLINICAL TRIALS; HUMANS; PIPECOLIC ACIDS;

EID: 33744992427     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.09.002     Document Type: Review

References (46)

1. Hursting M.J., Alford K.L., Becker J.C., et al. Novastan (brand of argatroban): a small molecule, direct thrombin inhibitor. Semin Thromb Hemost 23 (1997) 503-516
2. Berry C.N., Girardot C., Lecoffre C., et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 72 (1994) 381-386
3. Lunven C., Gauffeny C., Lecoffre C., et al. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 75 (1996) 154-160
4. Swan S.K., and Hursting M.J. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20 (2000) 318-329
5. Tran J.Q., Di Cicco R.A., Sheth S.B., et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 39 (1999) 513-519
6. Swan S.K., St. Peter J.V., Lambrecht L.J., et al. Comparison of anticoagulation effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 20 (2000) 756-770
7. Gold H.K., Torres F.W., Garabedian H.D., et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 21 (1993) 1039-1047
8. Jang I.K., Gold H.K., Leinbach R.C., et al. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 67 (1990) 1552-1561
9. Jang I.K., Gold H.K., Ziskind A.A., et al. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 81 (1989) 219-225
10. Jang I.K., Gold H.K., Leinbach R.C., et al. Persistent inhibition of arterial thrombosis by a 1-hour intravenous infusion of argatroban, a selective thrombin inhibitor. Coron Artery Dis 3 (1992) 407-414
11. Yasuda T., Gold H.K., Yaoita H., et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion, and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 16 (1990) 714-722
12. Yamada K., Tsuji J., Kimura S., et al. Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model. Thromb Res 109 (2003) 55-64
13. Morris D.C., Zhang L., Zheng G.Z., et al. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke 32 (2001) 2635-2640
14. Jang I.K., Brown D.R., Giugliano R.P., et al. A multi-center, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (tPA) in acute myocardial infarction: myocardial infarction with novastan and tPA (MINT) study. J Am Coll Cardiol 33 (1999) 1880-1885
15. Vermeer F., Vahanian A., Fels P.W., et al. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study. J Thromb Thrombolysis 10 (2000) 233-240
16. Behar S., Hod H., and Kaplinski E. Argatroban versus heparin as adjuvant therapy to thrombolysis for acute myocardial infarction: safety considerations-ARGAMI-2 Study. Circulation 98 Suppl 17 (1998) I453-I454
17. Cody R.J. Results from late breaking clinical trials session at ACC'97. J Am Coll Cardiol 30 (1997) 1-7
18. Lewis B.E., Matthai Jr. W.H., Cohen M., et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 57 (2002) 177-184
19. Jang I.K., Lewis B.E., Matthai W.H., et al. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, non-randomized pilot study. J Thromb Thrombolysis 18 (2004) 31-37
20. Cox D.S., Kleiman N.S., Boyle D.A., et al. Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention. J Clin Pharmacol 44 (2004) 981-990
21. Ohteki H., Furukawa K., Ohnishi H., et al. Clinical experience of argatroban for anticoagulation in cardiovascular surgery. Jpn J Thorac Cardiovasc Surg 48 (2000) 39-46
22. Ohno J., Higashidate M., and Yokosuka T. Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary bypass surgery. Heart Vessels 18 (2003) 40-42
23. Cannon M.A., Butteroworth J., Riley R.D., et al. Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery. Ann Thorac Surg 77 (2004) 711-713
24. Warkentin T.E. Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev Med 50 (1999) 129-147
25. Warkentin T.E., and Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am J Med 101 (1996) 502-507
26. Wallis D.E., Workman D.L., Lewis B.E., et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 106 (1999) 629-635
27. Walenga J.M., Jeske W.P., Fasanella A.R., et al. Laboratory diagnosis of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 5 Suppl 1 (1999) S21-S27
28. Lewis B.E., Wallis D.E., Leya F., et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163 (2003) 1849-1856
29. Lewis B.E., Wallis D.E., Berkowitz S.D., et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103 (2001) 1838-1843
30. LaMonte M.P., Brown P.M., and Hursting M.J. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 32 (2004) 976-980
31. Matthai W.H., Hursting M.J., Lewis B.E., et al. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res 116 (2005) 121-126
32. Warkentin T.E., and Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 (2001) 1286-1292
33. Refaai M.A., Laposata M., and Van Cott E.M. Clinical significance of a borderline titer in a negative ELISA test for heparin-induced thrombocytopenia. Am J Clin Pathol 119 (2003) 61-65
34. Kobayashi S., and Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 23 (1997) 531-534
35. LaMonte M.P., Marshall L.N., Wang D.Z., et al. Argatroban anticoagulation in patients with acute ischemic stroke. Stroke 35 (2004) 1677-1682
36. Sugg R.M., Pan J.K., Uchino K., et al. Tpa ARgatroban sTroke Study (TARTS). Stroke 36 (2005) 447
37. Luzzatto G., Bertoli M., Cella G., et al. Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb Res 89 (1998) 115-122
38. Murray P.T., Reddy B.V., Grossman E.J., et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 66 (2004) 2446-2453
39. Tang I.Y., Cox D.S., Patel K., et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 39 (2005) 231-236
40. Argatroban manufacturer's website. http://www.argatroban.com (15 March 2005).
41. Williamson D.R., Boulanger I., Tardiff M., et al. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 24 (2004) 409-414
42. Reichert M.G., MacGregor D.A., Kincaid E.H., et al. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 37 (2003) 652-654
43. Sheth S.B., DiCicco R.A., Hursting M.J., et al. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 85 (2001) 435-440
44. Harder S., Graff J., Klinkhardt U., et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time. Thromb Haemost 91 (2004) 1137-1145
45. Young G., Yonekawa K.E., Nakagawa P., et al. Recombinant factor VIIa reverses the anticoagulant effects of argatroban, bivalirudin, fondaparinux, enoxaparin, and heparin as assessed ex vivo by thromboelastography. Blood 104 (2004) Abstract
46. Malherbe S., Tsui B.C., Stobart K., et al. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 100 (2004) 443-445